Hoy, W. E. et al. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kidney Int. 81, 1026–1032 (2012).
Oda, T. & Yoshizawa, N. Factors affecting the progression of infection-related glomerulonephritis to chronic kidney disease. Int. J. Mol. Sci. 22, 905 (2021).
Beaton, A. et al. The American Heart Association’s Call to Action for Reducing the Global Burden of Rheumatic Heart Disease: A Policy Statement From the American Heart Association. Circulation 142, e358–e368 (2020).
Fleming-Dutra, K. E. et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. J. Am. Med. Assoc. 315, 1864–1873 (2016).
Grigoryan, L. et al. Self-medication with antimicrobial drugs in Europe. Emerg. Infect. Dis. 12, 452–459 (2006).
Wyber, R. et al. Ending rheumatic heart disease in Australia: the evidence for a new approach. Med. J. Aust. 213, S3–S31 (2020).
Marijon, E., Mirabel, M., Celermajer, D. S. & Jouven, X. Rheumatic heart disease. Lancet 379, 953–964 (2012).
Barron, J., Turner, R., Jaeger, M., Adamson, W. & Singer, J. Comparing the use of intravenous antibiotics under the medical benefit with the use of oral antibiotics under the pharmacy benefit in treating skin and soft tissue infections. Manag. Care 21, 44–52 (2012).
Boyler, P. A., Humair, J., Revaz, S. A. & Stalder, H. A cost-effectiveness analysis of recommended strategies for acute pharyngitis. J. Gen. Intern. Med. 17, 135–136 (2002).
Dall, L., Peterson, S., Simmons, T. & Dall, T. Outpatient treatment of CAP cellulitis generates cimost savings. Drug Benefit Trends 16, 21-22+24-28+32 (2004).
Eron, L. J., King, P. & Marineau, M. Antibiotic selection and hospital discharge of patients with cellulitis. Infect. Med. 21, 381–38 (2004).
Perone, N. & Humair, J. P. Diagnosis and management of pharyngitis. Rev. Med. Suisse 3, 286–290 (2007).
Yang, C. C. & Pan, C. Y. Evaluation of cost-effectiveness for prophylactic antibiotic in recurrent cellulitis of lower limb. J. Intern. Med. Taiwan 22, 352–362 (2011).
Baumann, I. Outcome after tonsillectomy in chronic tonsillitis. [German]. Hno 53, 405–407 (2005).
Love, B. L. & Kehr, H. Management of complicated skin and soft tissue infections in hospitalized patients. U. S. Pharmacist. 32, HS5–HS12 (2007).
Tang Girdwood, S. C. et al. Improving the transition of intravenous to enteral antibiotics in pediatric patients with pneumonia or skin and soft tissue infections. J. Hospital Med. 15, 9–15 (2020).
Cannon, J. W. et al. An economic case for a vaccine to prevent group A streptococcus skin infections. Vaccine 36, 6968–6978 (2018).
Burns, R. M. et al. Economic analysis of oral dexamethasone for symptom relief of sore throat: the UK TOAST study. Bmj Open 8, e019184 (2018).
Bura, M., Michalak, M., Chojnicki, M., Padzik, M. & Mozer-Lisewska, I. Moderate and severe pharyngitis in young adult inhabitants of Poznan, western Poland. Fam. Med. Prim. Care Rev. 19, 12–17 (2017).
Kose, E. et al. The effect of rapid antigen detection test on antibiotic prescription decision of clinicians and reducing antibiotic costs in children with acute pharyngitis. J. Trop. Pediatr. 62, 308–315 (2016).
Humair, J. P., Revaz, S. A., Bovier, P. & Stalder, H. Management of acute pharyngitis in adults – Reliability of rapid streptococcal tests and clinical findings. Arch. Intern. Med. 166, 640–644 (2006).
Portier, H. et al. Assessing applicability of guidelines on management of pharyngitis in adults in general practice. Med. Mal. Infect. 31, 396–402 (2001).
Nakhoul, G. N. & Hickner, J. Management of adults with acute Streptococcal Pharyngitis: minimal value for backup strep testing and overuse of antibiotics. J. Gen. Intern. Med. 28, 830–834 (2013).
Alfonso, K., Collazo, M., Fernandez, M. & Ballagas, C. Cost-efficacy analysis of topical ozonized oil versus mupirocin cream in the treatment of impetigo. Lat. Am. J. Pharm. 27, 512–518 (2008).
Anusha Rani, M. V., Bhuvaneshwari, E. & Venkatakrishna, A. Comparison of efficacy and cost-effectiveness of topical fusidic acid and topical mupirocin in the treatment of impetigo. Natl J. Physiol., Pharm. Pharmacol. 9, 1225–1229 (2019).
Vinken, A. et al. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model. J. Hosp. Infect. 49, S13–S24 (2001).
Vinken, A. G. et al. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals. Am. J. Ther. 10, 264–274 (2003).
Lodise, T. P., Palazzolo, C., Reksc, K., Packnett, E. & Redell, M. Comparisons of 30-day admission and 30-day total healthcare costs between patients who were treated with Oritavancin or Vancomycin for a skin infection in the outpatient setting. Open Forum Infect. Dis. 6, ofz475 (2019).
Terres, C. R. Pharmacoeconomic analysis of the treatment of complicated skin and soft tissue infections with tigecycline or the combination of vancomycin and aztreonam in Spain. [Spanish]. Pharmacoeconomics 5, 23–33 (2008).
Ibrahim, L. F. et al. Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis. Lancet Infect. Dis. 19, 1101–1108 (2019).
Li, D. G. et al. Outcomes of early dermatology consultation for inpatients diagnosed with cellulitis. Jama Dermatol. 154, 537–543 (2018).
Kameshwar, K., Karahalios, A., Janus, E. & Karunajeewa, H. False economies in home-based parenteral antibiotic treatment: a health-economic case study of management of lower-limb cellulitis in Australia. J. Antimicrob. Chemother. 71, 830–835 (2016).
Yarbrough, P. M., Kukhareva, P. V., Spivak, E. S., Hopkins, C. & Kawamoto, K. Evidence-based care pathway for cellulitis improves process, clinical, and cost outcomes. J. Hosp. Med. 10, 780–786 (2015).
Brugha, R. E. & Abrahamson, E. Ambulatory intravenous antibiotic therapy for children with Preseptal Cellulitis. Pediatr. Emerg. Care 28, 226–228 (2012).
Neuner, J. M., Hamel, M. B., Phillips, R. S., Bona, K. & Aronson, M. D. Diagnosis and management of adults with pharyngitis: a cost-effectiveness analysis. Ann. Intern. Med. 139, 113–122 (2003).
Van Howe, R. S. & Kusnier, L. P. Diagnosis and management of pharyngitis in a pediatric population based on cost-effectiveness and projected health outcomes. Pediatrics 117, 609–619 (2006).
Klepser, D. G., Bisanz, S. E. & Klepser, M. E. Cost-effectiveness of pharmacist-provided treatment of adult pharyngitis. Am. J. Manag. Care 18, E145–E150 (2012).
Behnamfar, Z., Shahkarami, V., Sohrabi, S., Aghdam, A. S. & Afzali, H. Cost and effectiveness analysis of the diagnostic and therapeutic approaches of group A Streptococcus pharyngitis management in Iran. J. Fam. Med. Prim. Care 8, 2942–2949 (2019).
Little, P. et al. PRImary care Streptococcal Management (PRISM) study: in vitro study, diagnostic cohorts and a pragmatic adaptive randomised controlled trial with nested qualitative study and cost-effectiveness study. Health Technol. Assess. 18, vii-xxv, 1–101 (2014).
Lloyd, A. & Pickard, A. S. The EQ-5D and the EuroQol Group. Value Health 22, 21–22 (2019).
Fraser, H. et al. Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation. Health Technol. Assess. 24, 1–+ (2020).
King, C. H., Fischler, D. F. & Gerkin, R. D. Will genetic testing alter the management of disease caused by infectious agents? A cost-effectiveness analysis of gene-testing strategies for prevention of rheumatic fever. Clin. Infect. Dis. 34, 1491–1499 (2002).
Irlam, J., Mayosi, B. M., Engel, M. & Gaziano, T. A. Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis a cost-effectiveness analysis. Circ.Cardiovasc. Qual. Outcomes 6, 343–351 (2013).
Ehrlich, J. E., Demopoulos, B. P., Daniel, K. R., Ricarte, M. C. & Glied, S. Cost-effectiveness of treatment options for prevention of rheumatic heart disease from group A streptococcal pharyngitis in a pediatric population. Prev. Med. 35, 250–257 (2002).
Giraldez-Garcia, C. et al. Diagnosis and management of acute pharyngitis in a paediatric population: a cost-effectiveness analysis. Eur. J. Pediatr. 170, 1059–1067 (2011).
Maizia, A., Letrilliart, L. & Colin, C. Diagnostic strategies for acute tonsillitis in France: a cost-effectiveness study. Presse Med. 41, e195–e203 (2012).
Nordet, P., Lopez, R., Duenas, A. & Sarmiento, L. Prevention and control of rheumatic fever and rheumatic heart disease: the Cuban experience (1986-1996-2002). Cardiovasc. J. Afr. 19, 135–140 (2008).
Watkins, D. A., Mvundura, M., Nordet, P. & Mayosi, B. M. A cost-effectiveness analysis of a program to control rheumatic fever and rheumatic heart disease in Pinar del Rio, Cuba. Plos One 10, e0121363 (2015).
Watkins, D., Lubinga, S. J., Mayosi, B. & Babigumira, J. B. A cost-effectiveness tool to guide the prioritization of interventions for rheumatic fever and rheumatic heart disease control in African Nations. PLoS Negl. Trop. Dis. 10, e0004860 (2016).
Manji, R. A. et al. Cost-effectiveness analysis of rheumatic heart disease prevention strategies. Expert Rev. Pharmacoecon. Outcomes Res. 13, 715–724 (2013).
Coates, M. M. et al. An investment case for the prevention and management of rheumatic heart disease in the African Union 2021-30: a modelling study. Lancet Glob. Health 9, E957–E966 (2021).
Soudarssanane, M. B. et al. Rheumatic fever and rheumatic heart disease: primary prevention is the cost effective option. Indian J. Pediatr. 74, 567–570 (2007).
Oetzel, J. G. et al. Efficacy of an incentive intervention on secondary prophylaxis for young people with rheumatic fever: a multiple baseline study. Bmc Public Health 19, 385 (2019).
Roberts, K. et al. Echocardiographic screening for rheumatic heart disease in indigenous Australian children: a cost-utility analysis. J. Am. Heart Assoc. 6, e004515 (2017).
Ubels, J. et al. Cost-effectiveness of rheumatic heart disease echocardiographic screening in Brazil: data from the PROVAR+ study. Glob. Heart 15, 18 (2020).
Zachariah, J. P. & Samnaliev, M. Echo-based screening of rheumatic heart disease in children: a cost-effectiveness Markov model. J. Med. Econ. 18, 410–419 (2015).
Uy, J., Ketkar, A. G., Portnoy, A. & Kim, J. J. Cost-utility analysis of heart surgeries for young adults with severe rheumatic mitral valve disease in India. Int. J. Cardiol. 338, 50–57 (2021).
Bhattacharyya, N. & Kepnes, L. J. Economic benefit of tonsillectomy in adults with chronic tonsillitis. Ann. Otol. Rhinol. Laryngol. 111, 983–988 (2002).
Wilson, J. A. et al. Tonsillectomy: a cost-effective option for childhood sore throat? Further analysis of a randomized controlled trial. Otolaryngol.-Head. Neck Surg. 146, 122–128 (2012).
Ostermann, T. et al. Cost-effectiveness analysis for SilAtro-5-90 adjuvant treatment in the management of recurrent tonsillitis, compared with usual care only. Cost. Eff. Resour. Alloc. 19, 60 (2021).
Mason, J. M. et al. Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials. PLoS ONE 9, e82694 (2014).
Drummond, M. F. et al. Methods for the Economic Evaluation of Health Care Programmes. 4th edn. (Oxford University Press, 2015).
Wyber, R. et al. Rheumatic heart disease in Indigenous young peoples. Lancet Child Adolesc. Health 5, 437–446 (2021).
Parks, T., Smeesters, P. R. & Steer, A. C. Streptococcal skin infection and rheumatic heart disease. Curr. Opin. Infect. Dis. 25, 145–153 (2012).
Thomas, S. et al. Descriptive analysis of group A Streptococcus in skin swabs and acute rheumatic fever, Auckland, New Zealand, 2010–2016. Lancet Regional Health – West. Pac. 8, 100101 (2021).
Lorgelly, P. K., Lawson, K. D., Fenwick, E. A. & Briggs, A. H. Outcome measurement in economic evaluations of public health interventions: a role for the capability approach? Int J. Environ. Res Public Health 7, 2274–2289 (2010).
Spinks, A., Glasziou, P. P. & Del Mar, C. B. Antibiotics for treatment of sore throat in children and adults. Cochrane Database Syst. Rev. 12, CD000023 (2021).
Bateman, E. et al. Examining the efficacy of antimicrobial therapy in preventing the development of postinfectious glomerulonephritis: a systematic review and meta-analysis. Infect. Dis. Rep. 14, 176–183 (2022).
de Almeida Torres, R. S. et al. Management of contacts of patients with severe invasive group A Streptococcal infection. J. Pediatr. Infect. Dis. Soc. 5, 47–52 (2016).
Moore, D. L., Allen, U. D. & Mailman, T. Invasive group A streptococcal disease: management and chemoprophylaxis. Paediatr. Child Health 24, 128–129 (2019).
Raff, A. B. & Kroshinsky, D. Cellulitis: a review. JAMA 316, 325–337 (2016).
Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, 71 (2021).